300+ investors in your industry, stage, and region Get
Any industry
Community
Proptech
Biotech
Climate
Artificial Intelligence
Media (Entertainment)
Impact
FinTech
Marketplace
EdTech
Consumer
Agriculture (AgTech)
Web3
Clean Energy
B2B
Organic Food
Big Data
Video Games
Payments
Celebrity
Franchise
Mobile
Local
Social Network
Platforms
Crowdfunding
CleanTech
Film
Theatre
Life Science
Non Profit
Transportation
Gaming
Energy
Hardware
Health Care
Enterprise
Sustainability
Venture Capital
Restaurants
Fashion
Real Estate
Retail
Infrastructure
Mobile Apps
Beauty
LGBT
Publishing
Sporting Goods
Oil and Gas
Education
Renewable Energy
Food and Beverage
Cryptocurrency
Finance
Financial Services
Photography
Art
Medical
Digital Media
Music
Internet
Social Media
Manufacturing
Facebook
Blockchain
Legal
Android
Social Impact
Google
Construction
Sports
eSports
Enterprise Software
Email
Wellness
Hospitality
Travel
Fitness
Mobile Advertising
Cannabis
Recruiting
Biotechnology
Medical Device
Wine and Spirits
Automotive
Social
InsurTech
SaaS
Software
Any country
Qatar
South Korea
Africa
Asia
LATAM
Europe
Oceania
Middle East
Ireland
Singapore
Indonesia
Spain
Saudi Arabia
Belarus
Belgium
Colombia
Denmark
Ecuador
Czech Republic
Estonia
Ghana
Ethiopia
Finland
Barbados
Italy
Jersey
Cayman Islands
Mali
Malaysia
Mauritius
Poland
Rwanda
Togo
Slovenia
San Marino
Tanzania
Thailand
Uruguay
Venezuela
Portugal
Azerbaijan
Namibia
Bolivia
Latvia
Cyprus
New Zealand
United States
Germany
Australia
India
United Kingdom
Canada
China
South Africa
Brazil
Japan
Sri Lanka
Vietnam
Argentina
Armenia
Austria
Bangladesh
Bahrain
Bulgaria
Bermuda
Chile
Cameroon
Switzerland
Belize
Costa Rica
Algeria
Georgia
Egypt
Hong Kong
Gibraltar
Faroe Islands
Greece
Croatia
France
Hungary
Kuwait
Israel
Lebanon
Cambodia
Kenya
Jordan
Lithuania
Liberia
Liechtenstein
Myanmar
Kazakhstan
Morocco
Norway
Mexico
Panama
Malta
Peru
Philippines
Nicaragua
Pakistan
Russian Federation
Romania
Sweden
Serbia
Seychelles
Turkey
Puerto Rico
Sierra Leone
Senegal
Tunisia
Tajikistan
El Salvador
Uganda
Zambia
Uzbekistan
Taiwan
Ukraine
Zimbabwe
Bahamas
Guatemala
Iraq
Iceland
Nigeria
United Arab Emirates
Honduras
Isle of Man
Luxembourg
Oman
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotech VC Funds & Investors in Australia (October 2023)

The most active venture capital funds investing in Australia Biotech startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Australia Biotech startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Uniseed Ventures
VC Fund
21 Australia, United States, United Kingdom Series A, Seed Biotechnology, Manufacturing, Health Care $364k–$6.4M
Brandon Capital Partners
VC Fund
15 Australia, United States, United Kingdom Series A, Seed, Series B Biotechnology, Health Care, Medical $642k–$25M
Medical Research Commercialisation Fund (MRCF)
VC Fund
11 Australia, United States, United Kingdom Series A, Seed, Series B Biotechnology, Health Care, Medical $1.3M–$13M
Stoic VC
VC Fund
7 Australia, United States, United Kingdom Seed, Series A Biotechnology, Medical, Health Care
OneVentures
VC Fund
6 Australia, United States, Israel Series A, Debt Financing Software, Health Care, Information Technology $1.5M–$20M
Artesian VC
VC Fund
5 Australia, United States, Hong Kong Seed, Series A, Pre-Seed Software, Artificial Intelligence, Information Technology $70k–$12M
Melbourne Angels
VC Fund
5 Australia, United States, New Zealand Angel, Seed Biotechnology, Information Technology, Manufacturing $32k–$893k
Main Sequence Ventures
VC Fund
4 Australia, United States, Philippines Series A, Seed, Series B Software, Artificial Intelligence, Information Technology $1.3M–$49M
Starfish Ventures
VC Fund
3 United States, Australia, Philippines Series A, Series B Software, Enterprise Software, Information Technology $642k–$14M
Clean Energy Finance Corporation
VC Fund
3 Australia, United States Series B, Series A, Seed Energy, Solar, Renewable Energy $2.5M–$19M
Horizons Ventures
VC Fund
3 United States, United Kingdom, Canada Series A, Series B, Seed Biotechnology, Artificial Intelligence, Software $750k–$70M
Yuuwa Capital
VC Fund
3 Australia Series A, Seed, Series B Biotechnology, Analytics, Health Care $128k–$6.1M
Brisbane Angels
VC Fund
2 Australia, United States, New Zealand Seed, Angel Software, Information Technology, Artificial Intelligence $321k–$835k
Folklore Ventures
VC Fund
2 Australia, New Zealand, United States Seed, Series A Software, Apps, Information Technology $250k–$15M
Grok Ventures
VC Fund
2 Australia, United States, Hong Kong Series A, Series B, Seed Renewable Energy, Software, Internet of Things $1M–$465M
Global Health Investment Fund (GHIF)
VC Fund
2 United States, India, Austria Series B, Series C Health Care, Biotechnology, Medical Device $4.5M–$17M
Vectr
VC Fund
2 United States, Hong Kong, Singapore Seed, Series A, Pre-Seed FinTech, Artificial Intelligence, Financial Services $425k–$35M
BridgeLane Capital
VC Fund
2 Australia, Germany Seed, Series B Software, Financial Services, Health Care $642k–$13M
South Australian Venture Capital Fund
VC Fund
2 Australia Series A, Series B Health Care, Biotechnology, SaaS
Lowercarbon Capital
VC Fund
2 United States, United Kingdom, France Seed, Series A Biotechnology, Renewable Energy, Energy $2.7M–$50M
Possible Ventures
VC Fund
2 Germany, Australia, United States Seed, Pre-Seed, Series A Software, Information Technology, Biotechnology $350k–$43M
Sydney Angels
VC Fund
2 Australia, United States Seed, Angel Software, SaaS, Apps $161k–$895k
Plymouth Growth
VC Fund
1 United States, Canada, Australia Series A, Series B Software, Information Technology, Enterprise Software $500k–$7.8M
Victoria University of Wellington
VC Fund
1
Agronomics
VC Fund
1 United States, Finland, Australia Seed, Series A, Series B Biotechnology, Food and Beverage, Food Processing $500k–$20M
AbbVie Biotech Ventures
VC Fund
1 United States, China, Italy Series A, Series B, Series C Biotechnology, Science/Engineering, Health Care $6M–$100M
Alta Partners
VC Fund
1 United States, United Kingdom, Spain Series B, Series C, Series A Biotechnology, Health Care, Medical $5.2M–$109M
Tenacious Ventures
VC Fund
1 Australia, United States Seed, Pre-Seed, Series A Agriculture, AgTech, Software $2M–$4M
HESTA
VC Fund
1 Australia Series A, Series B, Series C Sensor, Medical, Aerospace
Terra Rossa Capital
VC Fund
1 Australia Series A, Series B Health Care, Biotechnology, Medical Device
CaraMed Capital
VC Fund
1 Australia Seed Biotechnology
Innovation Capital
VC Fund
1 Australia Series A Software, Music and Audio, Internet $3.7M–$5M
Maropost Ventures
VC Fund
1 United States, Australia, Sweden Seed, Series A, Secondary Market Science/Engineering, Commerce/Shopping, Data and Analytics $1.1M–$10M
Transition Level Investments
VC Fund
1 Australia, United States Seed, Pre-Seed, Series A SaaS, Artificial Intelligence, Software $60k–$2.4M
AustralianSuper
VC Fund
1 Australia, United States, United Kingdom Series A, Series C Information Technology, Hotel, Solar
Southern Cross Venture Partners
VC Fund
1 United States, Australia, Singapore Series A, Series B Software, Energy, Science/Engineering $2M–$15M
Vaekstfonden
VC Fund
1 Denmark, United States, United Kingdom Seed, Pre-Seed Software, Science/Engineering, IT $431k–$4.6M
Accelerating Commercialisation - AusIndustry
VC Fund
1 Australia Grant, Pre-Seed Software, Mining, Hardware
BioScience Managers Limited
VC Fund
1 Canada, Australia Health Care, Pet, Medical
Closed Loop Partners
VC Fund
1 United States, United Kingdom, Chile Series A, Seed Recycling, Supply Chain Management, Artificial Intelligence $3.2M–$16M
Right Click Capital
VC Fund
1 Australia, Singapore, United States Seed, Series A Software, Artificial Intelligence, SaaS $64k–$15M
CP Ventures
VC Fund
1 Australia, United States, India Seed, Pre-Seed, Series A Software, Science/Engineering, Data and Analytics $364k–$12M
Hitachi Ventures
VC Fund
1 United States, Australia, United Kingdom Series C, Seed, Series A Science/Engineering, Software, AI $9.5M–$200M
Regal Funds Management
VC Fund
1 Australia, United States, United Kingdom Series B, Convertible Note Software, Financial Services, FinTech $1.6M–$25M
Hostplus
VC Fund
1 Australia, United States, United Kingdom Series B, Series C, Series A Science/Engineering, Software, Sustainability $15M–$84M
Powerhouse Ventures
VC Fund
1 United States, Australia, United Kingdom Seed, Series A, Pre-Seed Software, Energy, Solar $726k–$30M
UniSA Ventures
VC Fund
1 Australia Seed Software, Health Care, Biotechnology
GBS Ventures
VC Fund
1 United States, Australia, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical Device $2.1M–$55M
Negev Capital
VC Fund
1 United States, Canada, Australia Seed, Series A, Series B Biotechnology, Medical, Health Care $363k–$3.2M
Nanyang Ventures
VC Fund
1 Australia Series A Health Care, Biotechnology, Science/Engineering
Access all 50 VC funds in Australia Biotech startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Uniseed Ventures
VC Fund · Brisbane, Queensland, Australia · 21 investments in Australia Biotech startups

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Show more...

Investment focus

  • Industry: Biotechnology, Manufacturing, Health Care
  • Stage:Series A, Seed
  • Geography: Australia, United States, United Kingdom

Investor stats

  • Total investments: 56
  • Round size: Seed $364k–$2M; Series A $1.3M–$6.4M
  • Lead/follow: 13% lead, 87% follow
  • Last fund: May invest from a new fund soon — raised $13M in 2017

Portfolio highlights

  • Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
  • Morse Micro — Smarter, farther, better. Meet the latest Wi-Fi, HaLow, 802.11ah. 10X FARTHER>1Km range, 100x area, 1000x volume 10X EFFICIENCYMulti-year on a single
  • Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
Show all investments...

Brandon Capital Partners
VC Fund · Melbourne, Victoria, Australia · 15 investments in Australia Biotech startups

Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Seed, Series B
  • Geography: Australia, United States, United Kingdom

Investor stats

  • Total investments: 39
  • Round size: Seed $642k–$6.4M; Series A $4M–$20M; Series B $5M–$25M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $210M in 2019

Portfolio highlights

  • CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
  • Entact Bio — Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.
  • NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
Show all investments...

Medical Research Commercialisation Fund (MRCF)
VC Fund · Melbourne, Victoria, Australia · 11 investments in Australia Biotech startups

Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Seed, Series B
  • Geography: Australia, United States, United Kingdom

Investor stats

  • Total investments: 25
  • Round size: Series A $1.3M–$13M
  • Lead/follow: 28% lead, 72% follow

Portfolio highlights

  • Glyscend — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
  • Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
  • Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Show all investments...

Stoic VC
VC Fund · Sydney, New South Wales, Australia · 7 investments in Australia Biotech startups

Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Seed, Series A
  • Geography: Australia, United States, United Kingdom

Investor stats

  • Total investments: 20
  • Lead/follow: 5% lead, 95% follow

Portfolio highlights

  • Ena Respiratory — Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs.
  • BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture. Our high-level introduction and detailed insights into our innovative solutions, exceptional collaborations, and dedicated team make it easy to understand WHO we are, WHAT we do, and HOW we do it. Stay updated with valuable resources, customer portal, and regular content via our blog. Contact us today to collaborate and optimize your farm's productivity and sustainability.
  • Lenexa Medical — Lenexa Medical is driving towards better healthcare solutions for patients in hospital and aged-care by preventing pressure injuries and empowering clinicans.
Show all investments...

OneVentures
VC Fund · Sydney, New South Wales, Australia · 6 investments in Australia Biotech startups

OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.

Show more...

Investment focus

  • Industry: Software, Health Care, Information Technology
  • Stage:Series A, Debt Financing
  • Geography: Australia, United States, Israel

Investor stats

  • Total investments: 64
  • Round size: Series A $1.5M–$20M; Debt Financing $1.8M–$4M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: Likely still investing — raised $128M in 2022

Portfolio highlights

  • Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
  • BiVACOR — BiVACOR is a privately held company founded in 2008. Their staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, they have established a strong collaborative network that extends both nationally and internationally. Their worldheadquarters is located in Houston, Texas, USA, and their international office is in Brisbane, Australia.
  • ImmVirX — ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect.
Show all investments...

Artesian VC
VC Fund · Melbourne, Victoria, Australia · 5 investments in Australia Biotech startups, 13 in the past 12 months

Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Information Technology
  • Stage:Seed, Series A, Pre-Seed
  • Geography: Australia, United States, Hong Kong

Investor stats

  • Total investments: 172
  • Round size: Seed $96k–$2.4M; Pre-Seed $70k–$1.5M; Series A $3.3M–$12M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • ZoomAgri — ZOOMAGRI provides an assessment of agricultural commodities to all participants of Agri supply chain via AI, computer vision and IoT.
  • Supplynote — End-to-end supply chain management tool to track inventory, orders, payments and suppliers online
  • Navi Medical Technologies — Navi Medical Technologies is a medical device development company.
Show all investments...

Melbourne Angels
VC Fund · Melbourne, Victoria, Australia · 5 investments in Australia Biotech startups

Melbourne Angels was formed in Melbourne, Australia in early 2007. Melbourne Angels is the leading group of private investors in Victoria who actively invest in early stage and growth technology companies.The group has a strong and experienced core of members that generate deal flow, are experienced in evaluation of business propositions and actas mentors for the other members and the entrepreneurs. The members vary in age, gender, ethnicity, profession and type of experience. All members have experience of success at being entrepreneurial.This award winning group is consistently one of the most active startup investors in the country.

Show more...

Investment focus

  • Industry: Biotechnology, Information Technology, Manufacturing
  • Stage:Angel, Seed
  • Geography: Australia, United States, New Zealand

Investor stats

  • Total investments: 34
  • Round size: Seed $32k–$771k; Angel $601k–$893k
  • Lead/follow: 56% lead, 44% follow

Portfolio highlights

  • Tayble — Spend more time enjoying your food and less time waiting.We hate waiting...For anything...And food and drinks are no exception!If your hobbies include:- Waiting in line - Calling out to a waiter - Watching the kettle boil - Calculating your split of the billPLEASE DO NOT DOWNLOAD THIS APP... YOU'LL HATE IT!But if you're likeus...And want your food and drinks ready exactly when you are...Or to leave a restaurant without worrying about your bill...Then step right up, this bad boy's for you!With Tayble, you’ll never have to flag down a waiter... EVER!Simply order from your "Tayble"Or before you even arrive...Leave the rest to us and the 1,000's of minions in the cloud that keep this all running!You’ll be left asking where has this been all my life, guaranteed!*(Definitely not a real guarantee)
  • Insite AI — We create predictability for consumer brands in the unpredictable world of retail. Game-changing technology that attacks consumer brands' hardest problems.
  • Apop Imaging — Apop Imaging develops and commercialises novel imaging, diagnostic and therapeutic tools to improve patient outcomes based on our proprietary calcitonin receptor antibody technology.
Show all investments...

Main Sequence Ventures
VC Fund · Sydney, New South Wales, Australia · 4 investments in Australia Biotech startups, 15 in the past 12 months

We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Information Technology
  • Stage:Series A, Seed, Series B
  • Geography: Australia, United States, Philippines

Investor stats

  • Total investments: 65
  • Round size: Seed $1.3M–$6M; Series A $3.8M–$22M; Series B $12M–$49M
  • Lead/follow: 54% lead, 46% follow
  • Last fund: May invest from a new fund soon — raised $161M in 2021

Portfolio highlights

  • Endua — Endua is building the next generation of clean energy deep storage to power communities, remote industries and off-grid infrastructure at the flick of a switch - all day and night
  • Jdoodle — JDoodle is an Online Compiler, Editor, IDE for Java, C, C++, PHP, Perl, Python, Ruby and many more. You can run your programs on the fly online, and you can save and share them with others. Quick and Easy way to compile and run programs online.
  • Number 8 bio — Number 8 bio objective is to decarbonize agriculture while feeding the world's rising population. This can be accomplished by harnessing the power of trillions of carbon-hungry bacteria that feed on harmful greenhouse gases and turn them into profitable animal feeds.
Show all investments...

Starfish Ventures
VC Fund · Melbourne, Victoria, Australia · 3 investments in Australia Biotech startups

Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.

Show more...

Investment focus

  • Industry: Software, Enterprise Software, Information Technology
  • Stage:Series A, Series B
  • Geography: United States, Australia, Philippines

Investor stats

  • Total investments: 51
  • Round size: Series A $642k–$6.6M; Series B $2.5M–$14M
  • Lead/follow: 53% lead, 47% follow
  • Last fund: May invest from a new fund soon — raised $119M in 2008

Portfolio highlights

  • Aktana — Build stronger relationships with HCPs using Aktana's artificial intelligence (AI) platform for life sciences to optimize omnichannel engagement.
  • DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,136,169 freelance designers compete to create amazing designs for your business. Start Today!
  • Marani — Marani Health is developing a prenatal care platform which includes a wearable, textile-based product to measure key vital statistics of women and their developing fetus, for use during pregnancy, labor & delivery. The products utilize Artificial Intelligence to better assess health & wellness during pregnancy, labor & delivery. Maraniis collaborating with key partners including The Mayo Clinic.
Show all investments...

Clean Energy Finance Corporation
VC Fund · Sydney, New South Wales, Australia · 3 investments in Australia Biotech startups, 9 in the past 12 months

The Clean Energy Finance Corporation invests, applying commercial rigour, to increase the flow of finance into the clean energy sector. Their mission is to accelerate Australia's transformation towards a more competitive economy in a carbon constrained world, by acting as a catalyst to increase investment in emissions reduction. They do thisthrough an investment strategy focused on cleaner power solutions, including large and small-scale solar, wind and bioenergy; and a better built environment, with investments to drive more energy efficient property, vehicles, infrastructure and industry. The CEFC also invests with co-financiers to develop new sources of capital for the clean energy sector, including climate bonds, equity funds, aggregation facilities and other financial solutions. The CEFC operates under the Clean Energy Finance Corporation Act 2012.

Show more...

Investment focus

  • Industry: Energy, Solar, Renewable Energy
  • Stage:Series B, Series A, Seed
  • Geography: Australia, United States

Investor stats

  • Total investments: 41
  • Round size: Seed $6M–$16M; Series A $2.5M–$13M; Series B $5M–$19M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Infradebt — Infradebt t is a specialist fund manager providing clients with direct access to infrastructure private debt markets.
  • Gunn Agri Partners — Gunn Agri Partners is an agricultural investment company that offers advice and services for acquisitions, asset, farm, and fund management.
  • HydGene Renewables — Our mission is to accelerate adoption of low carbon technology by providing an alternative green hydrogen solution.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Horizons Ventures
VC Fund · Hong Kong, Hong Kong Island, Hong Kong · 3 investments in Australia Biotech startups, 17 in the past 12 months

Investing in the deep science and technology that can propel humanity towards a radically better future.

Show more...

Investment focus

  • Industry: Biotechnology, Artificial Intelligence, Software
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 216
  • Round size: Seed $750k–$11M; Series A $6M–$30M; Series B $8M–$70M
  • Lead/follow: 45% lead, 55% follow

Portfolio highlights

  • BioLoomics — BioLoomics is a preclinical stage biotechnology company that uses evolution in a microscope to develop drug discovery tools and protein drugs. Our VariVolve platform tests millions of protein designs for a targeted activity in hours, enabling efficient mining of the vast chemical space of protein designs. A strong advantage of our approach is theuse of whole intact cells as test vessels that capture complex drug behavior not attainable in conventional assays.
  • Erthos — erthos is a producer of biodegradable packaging materials intended to replace traditional polystyrene and polypropylene inputs.
  • ZeroAvia — ZeroAvia is producing the world's first practical zero emission aviation powertrain, initially targeting 20-seat airplanes to start replacing dirty jet fuel in regional transport
Show all investments...

Yuuwa Capital
VC Fund · Perth, Western Australia, Australia · 3 investments in Australia Biotech startups

Yuuwa Capital is a $40M early-stage venture capital firm based in Perth, Western Australia. They are actively seeking outstanding investment opportunities where Yuuwa can provide both capital and expertise to help founders, management and early investors to turn good ideas into great companies.

Show more...

Investment focus

  • Industry: Biotechnology, Analytics, Health Care
  • Stage:Series A, Seed, Series B
  • Geography: Australia

Investor stats

  • Total investments: 16
  • Round size: Seed $128k–$771k; Series A $964k–$4.2M; Series B $2.6M–$6.1M
  • Lead/follow: 63% lead, 37% follow

Portfolio highlights

  • Nexgen Plants Pty Limited — Healthy plants, healthy people, living planet. Nexgen develop's plants for future generations that will improve the environment and health of future generations.
  • icetana — icetana Motion Intelligence dramatically improves the active monitoring of security surveillance networks, with AI video anomaly detection and video analytics.
  • Agworld Pty Ltd — Agworld Farm Management software allows you to collect data at all levels and enables you to extract maximum value from this data; optimising profitability. The Agworld ecosystem is utilised by growers, agronomists and service providers on farms across the world.
Show all investments...

Brisbane Angels
VC Fund · Brisbane, Queensland, Australia · 2 investments in Australia Biotech startups

Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.

Show more...

Investment focus

  • Industry: Software, Information Technology, Artificial Intelligence
  • Stage:Seed, Angel
  • Geography: Australia, United States, New Zealand

Investor stats

  • Total investments: 28
  • Round size: Seed $347k–$835k; Angel $321k–$601k
  • Lead/follow: 17% lead, 83% follow

Portfolio highlights

  • Tribu — Here at tribu we aim to make running an MSP stress-free and simple. Remove complexity and repetitive shackles to give you the freedom in business so that you can have freedom in life.
  • Avasa — Avasa is a medical device company. It helps to improve surgical procedures by developing novel implantable devices.
  • One Key Access — One Key Access is an interface to the world of couriers to enable 24/7 frictionless deliveries.
Show all investments...

Folklore Ventures
VC Fund · Sydney, New South Wales, Australia · 2 investments in Australia Biotech startups

Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.

Show more...

Investment focus

  • Industry: Software, Apps, Information Technology
  • Stage:Seed, Series A
  • Geography: Australia, New Zealand, United States

Investor stats

  • Total investments: 31
  • Round size: Seed $250k–$4.8M; Series A $500k–$15M
  • Lead/follow: 61% lead, 39% follow
  • Last fund: May invest from a new fund soon — raised $40M in 2017

Portfolio highlights

  • Swoop Aero — Transforming how the world moves by making access to the skies seamless.
  • HealthMatch — HealthMatch is a medical technology company that applies machine learning and artificial intelligence to clinical data to save lives.We aim to dramatically accelerate patient recruitment to clinical trials, and progress life-saving cures onto the market faster than existing practices allow.For clinicians and patients, there is a real struggleto identify and find appropriate trials, particularly where the criteria relating to each trial is inconsistently articulated. HealthMatch encodes qualifying questions relating to each patients condition. The platform matches responses to its trial dataset, and confirms only the correct-match trials for that patient — thereby streamlining the identification of suitable trials and facilitating a patient’s application to those trials.With Ai and software at the core, HealthMatch delivers a radically simple product to match patients with drug trials, backed by an execution approach to data that is deceptively complex to achieve and replicate. In doing so, HealthMatch is dramatically changing an industry that has essentially not moved beyond telephones and excel spreadsheets.
  • SimConverse — SimConverse is a simulation platform that uses generative AI to play the role of any patient, colleague or casualty.
Show all investments...

Grok Ventures
VC Fund · Surry Hills, New South Wales, Australia · 2 investments in Australia Biotech startups, 6 in the past 12 months

Grok Ventures is a private investment company. They back world-class teams solving big problems to shape a better future. They invest in fast growing technology-enabled businesses.

Show more...

Investment focus

  • Industry: Renewable Energy, Software, Internet of Things
  • Stage:Series A, Series B, Seed
  • Geography: Australia, United States, Hong Kong

Investor stats

  • Total investments: 43
  • Round size: Seed $1M–$7.1M; Series A $2.6M–$75M; Series B $100M–$465M
  • Lead/follow: 33% lead, 67% follow

Portfolio highlights

  • Lydian — Lydian aims to accelerate the decarbonization of the chemical industry by electrifying the chemical production process. Founded in 2021 by Branko Zugic, Lydian is headquartered in
  • Loam Bio — Loam Bio is developing tech that allows for crops to be inoculated with symbiotic micro-organisms.
  • Fleet Space Technologies — Fleet is an agile, next generation connectivity company. Our mission is to Connect Everything using cutting-edge communications and space technologies to maximise the resource efficiency of human civilisation and enable the next industrial revolution with our free, ubiquitous connectivity platform.
Show all investments...

Global Health Investment Fund (GHIF)
VC Fund · New York, New York, United States · 2 investments in Australia Biotech startups

The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Series B, Series C
  • Geography: United States, India, Austria

Investor stats

  • Total investments: 18
  • Round size: Series B $7.5M–$17M; Series C $4.5M–$14M
  • Lead/follow: 39% lead, 61% follow
  • Last fund: May invest from a new fund soon — last raise in 2012

Portfolio highlights

  • Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
  • CXL Ophthalmics — CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally.
  • Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
Show all investments...

Vectr
VC Fund · Sheung Wan, Hong Kong Island, Hong Kong · 2 investments in Australia Biotech startups, 6 in the past 12 months

Vectr is a venture firm based in Hong Kong. They combine investment, creation and growth to deliver game-changing impact to teams ready to tackle global issues, transform industries and improve the lives of millions.That combines capital, creation and partnership to deliver game-changing impact. We strive to be the ideal partner for founders thatare building transformation products and looking to expand their businesses into asia.

Show more...

Investment focus

  • Industry: FinTech, Artificial Intelligence, Financial Services
  • Stage:Seed, Series A, Pre-Seed
  • Geography: United States, Hong Kong, Singapore

Investor stats

  • Total investments: 72
  • Round size: Seed $425k–$4M; Series A $1M–$35M
  • Lead/follow: 19% lead, 81% follow

Portfolio highlights

  • Percent — Unlock private credit investments with Percent. Access alternative investments on the platform powering the future of private markets.
  • Micro Connect — Micro Connect provides market infrastructure, fintech, and platform development.
  • MasterExchange — Trading platform for music rights leveraging emerging technology to create friction free and compliant investment opportunities to everyone.
Show all investments...

BridgeLane Capital
VC Fund · Sydney, New South Wales, Australia · 2 investments in Australia Biotech startups

The BridgeLane Group is a privately-owned asset management firm specialising in the agricultural, real estate and innovation sectors. A significant global player in agriculture with a multi-decade record in large scale farming, the Group has a proud history in residential property development, comme

Show more...

Investment focus

  • Industry: Software, Financial Services, Health Care
  • Stage:Seed, Series B
  • Geography: Australia, Germany

Investor stats

  • Total investments: 16
  • Round size: Seed $642k–$2M; Series B $5M–$13M
  • Lead/follow: 38% lead, 62% follow

Portfolio highlights

  • Agerris — Agerris is a field robotics and AI start-up for the agriculture industry, based on technology created at the Australian Centre for Field Robotics, the University of Sydney, where they have been developing air and ground robotic solutions for the agriculture industry since 2005.
  • Sprout Stack
  • Evrima Technologies — Our clinical trial recruitment and management services put participants first. Trusted, timely clinical trial results are a good thing - for everybody.
Show all investments...

South Australian Venture Capital Fund
VC Fund · Adelaide, South Australia, Australia · 2 investments in Australia Biotech startups

South Australian Venture Capital Fund - helping build dynamic and innovative South Australian startups / scaleups and accelerate their growth to a national and global scale.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, SaaS
  • Stage:Series A, Series B
  • Geography: Australia

Investor stats

  • Total investments: 4
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Lumary — Simplify Your Care Management Optimise Your Organisation Create Better Wellbeing
  • BiomeBank — BiomeBank is a clinical stage biotechnology company with a mission to treat our microbiome and prevent disease by restoring gut microbial ecology.
  • Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
Show all investments...

Lowercarbon Capital
VC Fund · New York, New York, United States · 2 investments in Australia Biotech startups, 32 in the past 12 months

Lowercarbon Capital backs kickass companies slashing CO2 emissions, sucking carbon out of the sky, and buying us time to unf**k the planet.

Show more...

Investment focus

  • Industry: Biotechnology, Renewable Energy, Energy
  • Stage:Seed, Series A
  • Geography: United States, United Kingdom, France

Investor stats

  • Total investments: 102
  • Round size: Seed $2.7M–$11M; Series A $6.5M–$50M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Dioxycle — Dioxycle is develop electrolyser solutions for carbon dioxide emissions.
  • Isometric — Isometric is a carbon removal registry and science platform
  • Arc Boats — Arc manufactures and sells high-performance electric boats for watersports.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Possible Ventures
VC Fund · Munich, Bayern, Germany · 2 investments in Australia Biotech startups, 26 in the past 12 months

Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.

Show more...

Investment focus

  • Industry: Software, Information Technology, Biotechnology
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Germany, Australia, United States

Investor stats

  • Total investments: 117
  • Round size: Seed $2M–$7M; Pre-Seed $350k–$2.5M; Series A $6.9M–$43M
  • Lead/follow: 3% lead, 97% follow

Portfolio highlights

  • Automata — Automata is a deep-tech company that creates products that empower people to automate physical work. The company's product, Eva, is a lightweight and affordable robot arm built for professionals in a production line, in a lab, a home workshop or even in a classroom. People don't need to be technical experts to communicate with robots. Theweb-based software platform can be programmed by anyone, anywhere, any time, from any device, making it easy to reconfigure for a wide range of different tasks.Automata was founded on 2015 and is headquartered in London, England.
  • Eden Brew — Eden Brew is a ground-breaking new way to enjoy dairy products sustainably and nutritiously.
  • Pow.bio — Pow.bio provides fermentation services for synthetic biology.
Show all investments...

Sydney Angels
VC Fund · Sydney, New South Wales, Australia · 2 investments in Australia Biotech startups

Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.

Show more...

Investment focus

  • Industry: Software, SaaS, Apps
  • Stage:Seed, Angel
  • Geography: Australia, United States

Investor stats

  • Total investments: 42
  • Round size: Seed $161k–$895k; Angel $330k–$890k
  • Lead/follow: 60% lead, 40% follow
  • Last fund: May invest from a new fund soon — last raise in 2016

Portfolio highlights

  • Kapiche — Instant insights. No set up or coding. The Kapiche feedback analytics platform helps you ingest and analyze mountains of customer feedback in minutes.
  • Remi AI — A.I-Powered Demand Forecasting, Supply Chain AI, & Price Optimisation | Remi AI
  • Trendspek — Trendspek is the drone data solution asset managers use to make empowered decisions and ensure absolute asset knowledge. Conduct complete visual inspections from any web browser. Extract detailed insights without a site visit. Use powerful tools to analyse the structure and build a complete picture of asset condition. Enhance predictive maintenanceby closely monitoring trends. View different models side by side to observe important differences. Refine your understanding of an ever-changing asset.
Show all investments...

Plymouth Growth
VC Fund · Ann Arbor, Michigan, United States · 1 investments in Australia Biotech startups

Growth Capital for Leading Midwest Tech Companies

Show more...

Investment focus

  • Industry: Software, Information Technology, Enterprise Software
  • Stage:Series A, Series B
  • Geography: United States, Canada, Australia

Investor stats

  • Total investments: 55
  • Round size: Series A $500k–$7.8M; Series B $750k–$7M
  • Lead/follow: 60% lead, 40% follow
  • Last fund: May invest from a new fund soon — last raise in 2017

Portfolio highlights

  • CloseSimple — CloseSimple is a real estate based software firm making conversation around buying or selling a house easier through Text Message & Email.
  • Deck Commerce — Deck Commerce Order Management System (OMS) simplifies complex order processes to empower retailers to curate the best customer experience.
  • Forj — Host your association's conferences, trade shows, or events on our highly customizable and interactive virtual event platform, backed by our customer success team.
Show all investments...

Victoria University of Wellington
VC Fund · Wellington, Wellington, New Zealand · 1 investments in Australia Biotech startups

A tradition of fostering strong global links in teaching and research and programmes of national significance and international quality.

Show more...

Investor stats

  • Total investments: 1
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
Show all investments...

Agronomics
VC Fund · Douglas, South Lanarkshire, United Kingdom · 1 investments in Australia Biotech startups, 6 in the past 12 months

Venture capital investment can raise funds for your small business. Venture Capital Firms in the UK like Agronomics is a biotech venture capital firm which invest into the clean meat sector.

Show more...

Investment focus

  • Industry: Biotechnology, Food and Beverage, Food Processing
  • Stage:Seed, Series A, Series B
  • Geography: United States, Finland, Australia

Investor stats

  • Total investments: 33
  • Round size: Seed $500k–$20M; Series A $6M–$20M
  • Lead/follow: 48% lead, 52% follow

Portfolio highlights

  • Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
  • Clean Food Group — Clean Food Group provides sustainable ‘CLEAN’ alternatives to these fats and oils, ranging from liquid oils like soybean to hard fats like palm oil, cocoa butter, and milk fat. Clean Food Group produces sustainable food ingredients that are better for our environment and health without compromising on teste or performance.
  • HydGene Renewables — Our mission is to accelerate adoption of low carbon technology by providing an alternative green hydrogen solution.
Show all investments...

AbbVie Biotech Ventures
VC Fund · North Chicago, Illinois, United States · 1 investments in Australia Biotech startups

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.

Show more...

Investment focus

  • Industry: Biotechnology, Science/Engineering, Health Care
  • Stage:Series A, Series B, Series C
  • Geography: United States, China, Italy

Investor stats

  • Total investments: 46
  • Round size: Series A $6M–$50M; Series B $12M–$100M; Series C $60M–$75M
  • Lead/follow: 17% lead, 83% follow

Portfolio highlights

  • Nitrase Therapeutics — Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
  • Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
  • AmbAgon Therapeutics — AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.
Show all investments...

Alta Partners
VC Fund · San Francisco, California, United States · 1 investments in Australia Biotech startups

Alta Partners is a leading healthcare and life sciences venture capital firm, helping entrepreneurs build high-impact companies since 1996.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series C, Series A
  • Geography: United States, United Kingdom, Spain

Investor stats

  • Total investments: 157
  • Round size: Series A $5.2M–$40M; Series B $16M–$58M; Series C $10M–$109M
  • Lead/follow: 23% lead, 77% follow
  • Last fund: May invest from a new fund soon — last raise in 2021

Portfolio highlights

  • Allakos — Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatoryresponses. Allakos was founded in 2012 and is headquartered in San Carlos, California.
  • BetterVet — At BetterVet.com, we believe pets deserve more than just a regular vet visit. We provide high quality mobile veterinary care. Book pet appointments online now!
  • Novome Biotechnologies — Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.
Show all investments...

Tenacious Ventures
VC Fund · Melbourne, Victoria, Australia · 1 investments in Australia Biotech startups

Tenacious Ventures - Australia's first and only dedicated agrifood tech VC firm.

Show more...

Investment focus

  • Industry: Agriculture, AgTech, Software
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Australia, United States

Investor stats

  • Total investments: 15
  • Round size: Seed $2M–$4M
  • Lead/follow: 53% lead, 47% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Azaneo — Azaneo develops lightning-fast electric weeding technology. Using only electrons - herbicide free.
  • Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
  • SwarmFarm Robotics — Global crop protection specialists ADAMA and Australian ag-tech company.
Show all investments...

HESTA
VC Fund · Melbourne, Victoria, Australia · 1 investments in Australia Biotech startups

HESTA Super Fund is the Australian industry superannuation fund for people working in health and community services. Become a member today.

Show more...

Investment focus

  • Industry: Sensor, Medical, Aerospace
  • Stage:Series A, Series B, Series C
  • Geography: Australia

Investor stats

  • Total investments: 4
  • Lead/follow: 17% lead, 83% follow

Portfolio highlights

  • Baraja — Baraja is a deep technology company that has reinvented LiDAR for self-driving vehicles. Our patented platform, Spectrum-Scan™, takes a fundamentally different approach to LiDAR. Instead of relying on fragile moving parts and oscillating mirrors, we simply refract light through a prism to scan the environment. This patented method allows us todeliver unprecedented range, precision, and reliability in even the most extreme environments.
  • Citadel Group Ltd — Citadel develops and delivers technology and education solutions to state and federal government departments, and the private sector in Australia. The company operates through Technology and Education segments. The Technology segment sells professional and managed services to government agencies and private enterprises. Its services includestrategic advice, program management, acquisition support, and quality assurance services through consulting, contracting, and placement mechanisms; technology and integration services; and software solutions, products, and managed services for digital health, diagnostic laboratories, and clinical applications. The Education segment delivers a range of nationally-accredited business qualifications that enable students to articulate into second year university or to gain practical skills for employment.
  • Gilmour Space Technologies — Gilmour Space is a rocket company in Australia that is developing and launching low-cost small satellite launch vehicles. All orbits, all planets: https://www.gspacetech.com
Show all investments...

Terra Rossa Capital
VC Fund · Adelaide, South Australia, Australia · 1 investments in Australia Biotech startups

Terra Rossa Capital Pty Ltd operates as a venture capital fund. The Company invests in life science companies. Terra Rossa Capital serves clients in Australia.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Series A, Series B
  • Geography: Australia

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Signostics — Signostics produces Biotech medical devices. Their flagship product, Signos, allows healthcare professionals to use ultrasound in their clinical practice. It offers ultrasound platform technology that clinicians can place in their pocket or wear around their neck like a stethoscope. Just as handheld devices transformed the business world, it isanticipated the Signos will change the way healthcare professionals practice medicine.Signostics was established in Adelaide, Australia in 2005 and expanded into the U.S. in 2008, dedicated to developing fast and affordable point‐of‐care medical devices. The company launched its first product into the veterinarian market in January 2009 andgained regulatory approvals to enter the human medical device market for the United States, Europe, and Australia in May 2009. Signostics has offices in Palo Alto, California and Adelaide, South Australia.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
CaraMed Capital
VC Fund · Auckland, Auckland, New Zealand · 1 investments in Australia Biotech startups

CaraMed Capital is a deep-health tech venture capital fund.

Show more...

Investment focus

  • Industry: Biotechnology
  • Stage:Seed
  • Geography: Australia

Investor stats

  • Total investments: 1
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Psylo — Psylo is an Australia-based psychedelic biotech business focusing on Psychedelic-inspired medicine to treat mental illness.
Show all investments...

Innovation Capital
VC Fund · Sydney, New South Wales, Australia · 1 investments in Australia Biotech startups

An Australian venture capital firm building global technology businesses

Show more...

Investment focus

  • Industry: Software, Music and Audio, Internet
  • Stage:Series A
  • Geography: Australia

Investor stats

  • Total investments: 6
  • Round size: Series A $3.7M–$5M
  • Lead/follow: 33% lead, 67% follow

Portfolio highlights

  • Audinate — Introducing Dante AV-H for H.26x video productsDante AV-H brings interoperability to AV-over-IP products, providing easy-to-use discovery, connectivity and manageability while using the familiar, reliable H.264/265 codecs already supported in common hardware./products/manufacturer-products/dante-av-video?link=hm-r2-lc-dc Dante Domain ManagerSecurity, organization, scalability, and control for Dante networksNow available with subscription pricing for all editions to fit your budget and purchasing needs […]
  • VPIsystems — VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated networkplanning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.
  • Weathertrends 360 — Weathertrends 360 is a global, web solution.
Show all investments...

Maropost Ventures
VC Fund · 1 investments in Australia Biotech startups

Maropost Ventures is a leading private equity firm that invests in people and their companies from the earliest days through all stages of Growth. SpaceX, Compono, Pressa and Lyres make up some of their first investments.

Show more...

Investment focus

  • Industry: Science/Engineering, Commerce/Shopping, Data and Analytics
  • Stage:Seed, Series A, Secondary Market
  • Geography: United States, Australia, Sweden

Investor stats

  • Total investments: 14
  • Round size: Seed $1.1M–$10M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Detected — Detected fills the critical KYB gap in the payments technology stack. Customers can complete Know Your Business requirements within their own CRM via API.
  • Exeger — We invent, engineer, and provide world-changing technologies to improve everyday life.
  • Lyre's Spirit Co — Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen.
Show all investments...

Transition Level Investments
VC Fund · Brisbane, Queensland, Australia · 1 investments in Australia Biotech startups

Founded by Steve Baxter, Transition Level Investments provides equity capital and operational expertise across Seed and Series A rounds to Australian companies. Our team focuses on a company-growth approach, adding value by assisting founders to build their expertise, expand their team, build product, scale locally and globally to position for asuccessful exit. We have a track record of identifying investment opportunities in the Australian market and helping enable global growth.

Show more...

Investment focus

  • Industry: SaaS, Artificial Intelligence, Software
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Australia, United States

Investor stats

  • Total investments: 17
  • Round size: Seed $835k–$2.4M; Pre-Seed $60k–$1.5M
  • Lead/follow: 35% lead, 65% follow

Portfolio highlights

  • Kapiche — Instant insights. No set up or coding. The Kapiche feedback analytics platform helps you ingest and analyze mountains of customer feedback in minutes.
  • FloodMapp — Enhance operational efficiency, lead time, situational awareness and decision making using FloodMapp rapid flood mapping software.
  • Chipper Cash — Join over 5 million people securely sending and receiving money with Chipper Cash. Great app to send and receive money across a number of countries, highly recommended as a money transfer alternative.
Show all investments...

AustralianSuper
VC Fund · Melbourne, Victoria, Australia · 1 investments in Australia Biotech startups

AustralianSuper is run only to benefit members, offering low fees and strong long-term investment returns.

Show more...

Investment focus

  • Industry: Information Technology, Hotel, Solar
  • Stage:Series A, Series C
  • Geography: Australia, United States, United Kingdom

Investor stats

  • Total investments: 8
  • Lead/follow: 38% lead, 62% follow

Portfolio highlights

  • Peel Ports — Peel Ports is a unique network of strategically situated ports, terminals, hubs, shipping lines, and state-of-the-art services.
  • SiteMinder — SiteMinder is the world’s leading open hotel commerce platform, ranked among technology pioneers for opening up every hotel’s access to online commerce. It’s this central role that has earned SiteMinder the trust of tens of thousands of hotels, across 150 countries, to sell, market, manage and grow their business. The global company, headquarteredin Sydney with offices in Bangkok, Berlin, Dallas, Galway, London and Manila, generated more than 100 million reservations worth over US$35 billion in revenue for hotels in the last year prior to the start of the pandemic.
  • Generate Capital — Generate Capital is a finance company that builds, owns, and operates sustainable infrastructure to deliver affordable and reliable resource solutions. The company operates and finances assets in energy, mobility, and water resources.
Show all investments...

Southern Cross Venture Partners
VC Fund · North Sydney, New South Wales, Australia · 1 investments in Australia Biotech startups

Southern Cross Venture Partners was launched in 2006 by veteran venture capitalists who have managed and operated companies themselves. Southern Cross Venture Partners assist early stage technology companies that demonstrate the potential for exceptional growth and market leadership build significant businesses. The founding principle of SouthernCross is partnership -- they are passionately committed to doing everything they can to help their portfolio companies succeed. Their team has a strong record of utilizing their start-up and management experience, industry knowledge, network of business/customer relationships, and recruiting skills to assist in building significant shareholder value.Southern Cross is currently investing in companies that fit their investment criteria. They prefer to act as lead or co-lead in the early stages where they have experience that can help build value rapidly. They do not have a minimum investment amount, however, a typical initial investment will be $2 million to $5 million with an ability to invest more money in later rounds.

Show more...

Investment focus

  • Industry: Software, Energy, Science/Engineering
  • Stage:Series A, Series B
  • Geography: United States, Australia, Singapore

Investor stats

  • Total investments: 49
  • Round size: Series A $2M–$5M; Series B $5M–$15M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — raised $128M in 2012

Portfolio highlights

  • Sunman — Sunman Energy is a technology company founded by a group of industry veterans delivering the future of Solar. Through the research and development of composite materials, Sunman has successfully commercialized the world’s first glass-free, lightweight and flexible Panel – eArc. Replacing glass completely, eArc brings solar power to markets andapplication scenarios that were previously impossible.
  • Wave Computing — The future of high-tech in online casino is a bright one. For example, RFID technology will help casinos track and identify stolen chips. In addition, these systems can also predict player behavior and betting patterns. The latter are especially useful if a player is caught while he is trying to switch out his cards. These ... Read more
  • Brisbane Materials Technology — Brisbane Materials aims to be the leading supplier of anti-reflective and anti-soiling coatings for solar and other applications. Born out of the University of Queensland in 2005, Brisbane Materials builds on six years and significant investment in technology and application experience. Longer term, Brisbane Materials will extend its unique roomtemperature and atmospheric pressure synthesis of glass and ceramic coatings to a wide variety of materials systems and applications.
Show all investments...

Vaekstfonden
VC Fund · Hellerup, Hovedstaden, Denmark · 1 investments in Australia Biotech startups, 20 in the past 12 months

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Show more...

Investment focus

  • Industry: Software, Science/Engineering, IT
  • Stage:Seed, Pre-Seed
  • Geography: Denmark, United States, United Kingdom

Investor stats

  • Total investments: 180
  • Round size: Seed $790k–$4.6M; Pre-Seed $431k–$1.2M
  • Lead/follow: 29% lead, 71% follow

Portfolio highlights

  • Wedio — Rent professional film equipment from trusted creators near you. Hire cameras, lenses, drones with Global Coverage.
  • Uniify — Uniify is a no-code customer onboarding software that makes it fast, easy and secure for financial companies to onboard their customers. Save your business time and money, and build onboarding flows for your customers in minutes instead of months.
  • Multiscription — Multiscription is a cross-product subscription service. Introducing Unleashd, the first in-game and cross-publisher subscription service for free-to-play games.
Show all investments...

Accelerating Commercialisation - AusIndustry
VC Fund · Canberra, Australian Capital Territory, Australia · 1 investments in Australia Biotech startups

A grant program offered by AusIndustry as part of the Australian Government’s National Innovation and Science Agenda

Show more...

Investment focus

  • Industry: Software, Mining, Hardware
  • Stage:Grant, Pre-Seed
  • Geography: Australia

Investor stats

  • Total investments: 2
  • Lead/follow: 50% lead, 50% follow

Portfolio highlights

  • Neuromersiv — Neuromersiv empowers stroke and brain injury survivors with clinically designed virtual reality-based neurological rehabilitation solutions.
  • Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
Show all investments...

BioScience Managers Limited
VC Fund · Melbourne, Victoria, Australia · 1 investments in Australia Biotech startups

BioScience Managers Pty Ltd (formerly IB Managers) is a leading life sciences investment firm, headquartered in Melbourne, Australia. Established in 2003, BioScience Managers offers a global, multi-disciplinary team, bringing an international perspective together with the track record, networks and expertise required to convert that perspectiveinto informed, high return investment decisions.We operate a high value-add model, providing assistance and support to portfolio companies via our global team and international network of independent industry advisors. With combined experience of over 170 investments, more than 40 IPO’s/ reversals in Europe, the USA and Australia, and a diverse skillset specific to the bio-based industries, we aim to provide investee companies with significant value-add over and above capital invested.Alongside our funds management business, Phillip Bioscience Advisory provides specialist corporate advisory services to healthcare and life sciences companies.

Show more...

Investment focus

  • Industry: Health Care, Pet, Medical
  • Geography: Canada, Australia

Investor stats

  • Total investments: 2
  • Lead/follow: 33% lead, 67% follow

Portfolio highlights

  • Nexvet — Our mission is to be a revolutionary force in the growing US$25 billion global animal pharmaceutical market. Only Nexvet can produce therapeutic antibodies that are 100% customised to target new species – like cats and dogs.Monoclonal antibody therapies have represented a new generation of highly effective, safe and targeted medicines inhumans. We think it’s time companion animals reaped the benefits of human medical progress in this field.Nexvet’s unique technology, PETisation™, ensures 100% customisation of a therapy to a new species, reducing the chances of immune challenges, and ensuring a more ‘natural’ fit between the therapy and the patient. Many chronic conditions in pets remain poorly treated by current veterinary therapies, such as pain and various inflammatory diseases– which has guided Nexvet’s focus towards these indications.To ensure we succeed in transforming animal medicine, we’ve brought together a team with an extraordinary global track record in animal and human health. We are working with leading contractors, advisors, drug development partners, academic groups, veterinarians and animal interest groups around the world to develop our pipeline to the highest standards.Senior executives and researchers from the world’s largest animal health brands are counted among our Board, management, and advisors, and together we’re building connections worldwide to make our vision a reality.
  • Canary Medical — Canary is giving medical devices a voice and letting medical data be heard.
Show all investments...

Closed Loop Partners
VC Fund · New City, New York, United States · 1 investments in Australia Biotech startups

We Invest in the Circular Economy, a New Economic Model Focused on a Profitable and Sustainable Future.

Show more...

Investment focus

  • Industry: Recycling, Supply Chain Management, Artificial Intelligence
  • Stage:Series A, Seed
  • Geography: United States, United Kingdom, Chile

Investor stats

  • Total investments: 29
  • Round size: Seed $3.2M–$6M; Series A $6M–$16M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
  • EcoSpirits — The World's first low carbon, low waste spirits distribution technology. Join the revolution. End single use glass.
  • Solarcycle — We offer solar asset owners a low-cost, eco-friendly, comprehensive process for retiring solar panels and repurposing them for new uses.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Right Click Capital
VC Fund · Sydney, New South Wales, Australia · 1 investments in Australia Biotech startups

Right Click Capital - Australian Venture Capital Firm

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, SaaS
  • Stage:Seed, Series A
  • Geography: Australia, Singapore, United States

Investor stats

  • Total investments: 55
  • Round size: Seed $64k–$3M; Series A $3.1M–$15M
  • Lead/follow: 25% lead, 75% follow
  • Last fund: May invest from a new fund soon — last raise in 2017

Portfolio highlights

  • Cydarm — A case management platform that enables cybersecurity operations teams to collaborate, integrate, and respond with ease.
  • Reejig — At Reejig, we believe in zero wasted potential in people and in business – and that starts with harnessing the skills you have within your organisation. Our workforce intelligence platform provides 100% visibility of your people’s skills, potential, passions and experiences, creating a powerful central nervous system for all talent decisions.Powered by the world’s first independently audited Ethical Talent AI engine, Reejig generates the intelligence to instantly fill roles, track retention risks, mobilise talent to opportunities, pivot talent for reskilling and much more. Plus, we give you the power to ‘nudge’ people to new career opportunities, taking your engagement with internal and external talent to the next level. Put simply, we make workforce agility a reality.Reejig is trusted and used by some of the largest and most complex organisations including Woolworths, KPMG, NSW Government, John Holland, MYOB and UTS, and together we are creating a world where everyone can reach their full potential at work. It’s what we call zero-wasted potential in people and in business.
  • Nomad Atomics — At Nomad Atomics, we develop innovative quantum sensors to solve outstanding problems in mining, underground resources and navigation
Show all investments...

CP Ventures
VC Fund · Sydney, New South Wales, Australia · 1 investments in Australia Biotech startups

CP Ventures is a VC fund that invests internationally in early stage, highly scalable, breakthrough technology companies driven by the 4IR

Show more...

Investment focus

  • Industry: Software, Science/Engineering, Data and Analytics
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Australia, United States, India

Investor stats

  • Total investments: 50
  • Round size: Seed $364k–$4M; Pre-Seed $800k–$900k; Series A $5.1M–$12M
  • Lead/follow: 46% lead, 54% follow

Portfolio highlights

  • Tpaga — Tpaga is a mobile wallet for unbanked consumers in Latin America. Currently in Colombia and Mexico.In Latin America, more than 50% do not have credit cards or bank accounts, but what they do have is a cellphone. Tpaga allows consumers to store money via cash kiosk ( 4,000 in our network) and then use it to pay utility bills, cell phone top-up,supermarket and even gas station merchants. We have become the first mobile wallet in Latin America to allow consumers to pay groceries without having a bank account, and allowing unbanked commerces to start receiving payment without have POS systems.
  • Anility — Embed financial health insights within your application using our world leading API service
  • Ensuredit — ENSUREDIT enables and empowers end customers and Insurance Intermediaries with AI-based product platforms for transformational customer experience.
Show all investments...

Hitachi Ventures
VC Fund · München, Bayern, Germany · 1 investments in Australia Biotech startups

Hitachi Ventures invests in innovative companies that address society’s key technological challenges in areas like IT, industrial automation (robotics, sensor technology and IoT), cloud services (data management, cybersecurity), mobility (autonomous driving, mobility services, smart infrastructure and security services), energy, smart medicine (AIfor digital imaging, smart diagnostics, remote care), smart city, smart infrastructure and more. With our first fund of USD 150M, we invest in Series A/B/C rounds in globally leading startups. From our offices in Munich, Germany, and Boston, USA, we work tirelessly to develop close ties and effective collaboration with leading innovative technology hubs and like-minded co-investors. Hitachi intends to leverage its strong position in multiple global technology markets, its expertise and network to support and promote Hitachi Ventures portfolio companies.

Show more...

Investment focus

  • Industry: Science/Engineering, Software, AI
  • Stage:Series C, Seed, Series A
  • Geography: United States, Australia, United Kingdom

Investor stats

  • Total investments: 14
  • Round size: Series A $9.5M–$12M; Series C $37M–$200M
  • Lead/follow: 29% lead, 71% follow

Portfolio highlights

  • Proscia — Concentriq, our digital pathology platform, is redefining the pathology laboratory. Learn about our AI-powered, computational pathology software here.
  • BeZero Carbon — BeZero Carbon is a global ratings agency for the Voluntary Carbon Market. Our carbon credit ratings allow all market participants to price and manage risk.
  • Scipher Medicine — At Scipher Medicine, we are committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. We have built a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, we canpredict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For our first commercial product, we have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs.We also used a different one for the ACO Payer Summit, I’ve provided that as well: Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Show all investments...

Regal Funds Management
VC Fund · Sydney, New South Wales, Australia · 1 investments in Australia Biotech startups

Regal Funds Management was founded in 2004 by Andrew and Philip King. Regal utilises a long/short investment strategy and performs investment management and investment advisory services to a number of Australian Unit Trusts and Cayman Island Companies.

Show more...

Investment focus

  • Industry: Software, Financial Services, FinTech
  • Stage:Series B, Convertible Note
  • Geography: Australia, United States, United Kingdom

Investor stats

  • Total investments: 71
  • Round size: Series B $7M–$25M; Convertible Note $1.6M–$16M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: Likely still investing — raised $48M in 2022

Portfolio highlights

  • Nykaa — Nykaa is an e-Commerce platform for different beauty and wellness products for men and women. They also offer comprehensive content including product reviews, beauty how-to videos, articles by experts, and an e-beauty magazine. Their helpline helps to choose products and services best suited for customer's needs. Nykaa's products areauthentic sourced directly from brands and provide a delivery experience.Nykaa was founded in 2012 by Falguni Nayar and is headquartered in Mumbai, Maharashtra, India.
  • SendFX — SendFX provides cross-border payment and remittance services to individuals and SMEs.
  • Send Payments — Send is a fast-growing fintech delivering embedded finance solutions to well-known brands.
Show all investments...

Hostplus
VC Fund · Melbourne, Victoria, Australia · 1 investments in Australia Biotech startups, 10 in the past 12 months

Join our leading Australian superannuation fund, committed to putting our members first, with a low admin fee and strong returns. Become a member today!

Show more...

Investment focus

  • Industry: Science/Engineering, Software, Sustainability
  • Stage:Series B, Series C, Series A
  • Geography: Australia, United States, United Kingdom

Investor stats

  • Total investments: 35
  • Round size: Series A $15M–$84M; Series B $23M–$42M; Series C $43M–$60M
  • Lead/follow: 12% lead, 88% follow

Portfolio highlights

  • Diffblue — Diffblue helps accelerate your shift left by automatically writing suites of unit regression tests so you can catch errors faster and earlier in your pipeline
  • Vow — Vow is crafting a new category of food
  • Oxbotica — Autonomous Vehicle Software - Any Vehicle, Any Place, Any Time
Show all investments...

Powerhouse Ventures
VC Fund · Oakland, California, United States · 1 investments in Australia Biotech startups

Powerhouse Ventures backs entrepreneurs building the digital infrastructure for rapid decarbonization.

Show more...

Investment focus

  • Industry: Software, Energy, Solar
  • Stage:Seed, Series A, Pre-Seed
  • Geography: United States, Australia, United Kingdom

Investor stats

  • Total investments: 41
  • Round size: Seed $726k–$3.5M; Series A $8.2M–$30M
  • Lead/follow: 10% lead, 90% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Tyba — Tyba provides end-to-end modeling of standalone and hybrid storage projects from early-stage development through operations, giving your business the edge to build and operate the best projects faster and more profitably.
  • Axiom Cloud — Axiom Cloud Inc. uses AI to solve the biggest energy and maintenance problems plaguing the underserved commercial cooling/refrigeration industry ($120B/year in the US alone). Our first target customer segment is retail grocery. Customers pay an initial setup fee to install/configure the IoT platform onsite, along with recurring SaaSfees for one or more cloud-based software apps that run on the IoT platform.
  • Granular Energy — Granular Energy provides solutions for managing and trading clean energy. Our tools have been developed to support the recent emergence of 24/7 time-stamped energy certificates as well as traditional "annual" certificates.
Show all investments...

UniSA Ventures
VC Fund · 1 investments in Australia Biotech startups

UniSA Ventures is the technology commercialisation and investment management company of the University of South Australia (UniSA).

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed
  • Geography: Australia

Investor stats

  • Total investments: 2
  • Lead/follow: 50% lead, 50% follow

Portfolio highlights

  • Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
  • Framework — All-in-one productivity tool for teams & individuals.
Show all investments...

GBS Ventures
VC Fund · Melbourne, Victoria, Australia · 1 investments in Australia Biotech startups

Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnologyproduct development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical Device
  • Stage:Series A, Series B, Series C
  • Geography: United States, Australia, United Kingdom

Investor stats

  • Total investments: 34
  • Round size: Series A $2.1M–$9M; Series B $9.3M–$20M; Series C $3M–$55M
  • Lead/follow: 20% lead, 80% follow

Portfolio highlights

  • Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
  • Elastagen — Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial. Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen hasdeveloped a synthetic version of the elastin protein which is identical to that naturally present in the human body. Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair. Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups. Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.
  • AirXpanders — AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.
Show all investments...

Negev Capital
VC Fund · Grand Cayman, Midland, Cayman Islands · 1 investments in Australia Biotech startups

Psychedelic Medical Intervention Investment Fund

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Seed, Series A, Series B
  • Geography: United States, Canada, Australia

Investor stats

  • Total investments: 6
  • Round size: Seed $363k–$3.2M
  • Lead/follow: 33% lead, 67% follow

Portfolio highlights

  • Psylo — Psylo is an Australia-based psychedelic biotech business focusing on Psychedelic-inspired medicine to treat mental illness.
  • Mindstate Design Labs — A psychedelic drug development company designing altered states of consciousness for mental health therapeutics.
  • Delix Therapeutics — Rewiring the brain to heal the mind
Show all investments...

Nanyang Ventures
VC Fund · Sydney, New South Wales, Australia · 1 investments in Australia Biotech startups

Nanyang Ventures invests with the aim of building listable companies. Company spokesman John Mulquiney said the Genetic Solutions management team had been successful at commercialising the company's technology.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Science/Engineering
  • Stage:Series A
  • Geography: Australia

Investor stats

  • Total investments: 1
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • QRxPharma — QRxPharma is an Australian-based, commercial-stage specialty pharmaceutical company focused on the development and commercialization of new pain management and abuse prevention productsBased on a development strategy that focuses on enhancing the clinical utility of currently approved compounds as well as bringing new products to market, thecompany's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes.In Q4 2013, the Company plans to refile with the US Food and Drug Administration a New Drug Application for its lead product candidate, immediate release MOXDUO®, for the treatment of acute pain. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc. and Aspen Group for the commercialisation of immediate release MOXDUO in the US, Canada, Australia (including New Zealand and Oceania) and South Africa.The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of MOXDUO. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology.
Show all investments...

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotech VC Funds in Australia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 48,091 VC funds investing in Australia Biotech startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists

Broader lists